Thiruppathi Govindhan

Dr. Thiruppathi Govindhan


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
Arvind Kumar ShuklaArvind Kumar Shukla
Arvind Kumar Shukla
Sandhya A. ShuklaSandhya A. Shukla
Sandhya A. Shukla
SSSonali Pradeep Suryawanshi
Sonali Pradeep Suryawanshi
Adarsha Mahendra UpadhyayAdarsha Mahendra Upadhyay
Adarsha Mahendra Upadhyay
NRNavin Ray
Navin Ray
RMRAJ MONGRE
RAJ MONGRE
Recent advancements in three-dimensional (3D) bioprinting have revolutionized the modeling of skin cancer, enabling the fabrication of high-throughput, patient-specific organoids that recapitulate the structural, functional, and microenvironmental complexity of native tumors. This review focuses on the integration of cutting-edge bioprinting technologies with bioengineered extracellular matrices and patient-derived cells to generate physiologically relevant skin cancer models for diagnostic and personalized medicine applications. Key technological innovations, including novel bioinks, multi-material printing strategies, and biomimetic approaches, are discussed for their ability to replicate tumor-stroma interactions, vascularization, and immune microenvironments. The utility of bioprinted organoids in high-throughput drug screening, mutation-targeted therapy design, and biomarker discovery is critically evaluated. Additionally, we address current challenges in standardization, reproducibility, and clinical translation, highlighting regulatory and quality-control considerations. Collectively, this review emphasizes the transformative potential of 3D bioprinted skin cancer organoids as platforms for precision oncology, bridging bioengineering advances with translational research to accelerate therapeutic development and personalized treatment strategies.

5 November 2025 in Organoids
Verified
Journal Article
Open access
PDF file
Arvind Kumar ShuklaArvind Kumar Shukla
Arvind Kumar Shukla
Sandhya A. ShuklaSandhya A. Shukla
Sandhya A. Shukla
RMRAJ MONGRE
RAJ MONGRE
Adarsha Mahendra UpadhyayAdarsha Mahendra Upadhyay
Adarsha Mahendra Upadhyay
TGThiruppathi Govindhan
Thiruppathi Govindhan
Sayan Deb DuttaSayan Deb Dutta
Sayan Deb Dutta
Breast cancer remains one of the leading causes of cancer morbidity and mortality among women worldwide. Conventional two-dimensional (2D) cell culture models and animal studies often fail to accurately recapitulate the complex tumor microenvironment and heterogeneous nature of breast cancer. Recent advancements in tissue engineering have enabled the development of more physiologically relevant models using three-dimensional (3D) bioprinting and organoid technology. This study focuses on integrating 3D bioprinting with patient-derived organoid models to replicate breast cancer tissue architecture, cellular heterogeneity, and tumor-stroma interactions. Utilizing biomimetic bioinks and customized bioprinting protocols, we successfully fabricated breast cancer tissue constructs embedded with stromal and immune components. These engineered models demonstrated high fidelity in mimicking in vivo tumor pathophysiology, including angiogenesis, epithelial–mesenchymal transition, and extracellular matrix remodeling. Furthermore, the platform allowed for high-throughput drug screening and evaluation of therapeutic responses, revealing differential sensitivities to chemotherapeutics and targeted therapies. Our findings highlight the potential of bioprinted organoid models as powerful tools for personalized medicine, enabling more predictive and reliable cancer research and drug development.

22 September 2026 in Indian Journal of Microbiology
Verified
Journal Article
Closed access
PDF file
TGThiruppathi Govindhan
Thiruppathi Govindhan
LPLeela Palanisamy
Leela Palanisamy
SSSundar Sundararaj
Sundar Sundararaj